Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate 50% Clear all
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

NCT00060346
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
153
States / cities
Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Eleview Versus Hetastarch as Injectate for EMR

NCT03350217
View directory record Official record
Conditions
Procedural Bleeding, Delayed Bleeding, Post-Polypectomy Syndrome, Post Procedural Complication
Interventions
Eleview, Hetastarch
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

NCT02937168
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

NCT01161550
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine, All-Trans Retinoic Acid (ATRA), Midostaurin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Rhodiola Rosea Therapy of Major Depressive Disorder

NCT01098318
View directory record Official record
Conditions
Depression
Interventions
Herbal extract, Sertraline, Lactose monohydrate
Dietary Supplement · Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

NCT02502708
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
Interventions
Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
3 Years to 21 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

NCT00088374
View directory record Official record
Conditions
Hippel-Lindau Disease, Kidney Cancer
Interventions
17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 14, 2026, 9:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

NCT06820658
View directory record Official record
Conditions
Healthy, Insulin Resistance
Interventions
Neuromuscular Test, DEXA, Mixed Meal Tolerance Test, Strength Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Withdrawn Phase 2 Interventional

Safety of Heparin in Patients With Septic Shock

NCT01234285
View directory record Official record
Conditions
Sepsis
Interventions
heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 14, 2026, 9:53 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

NCT05541887
View directory record Official record
Conditions
Cognitive Performance, Memory, Mood, Anxiety
Interventions
Muscadine Wine Polyphenol, Placebo
Other
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers

NCT01806415
View directory record Official record
Conditions
Healthy
Interventions
Fenobam, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of High Fat Diet on Muscle Metabolism

NCT02328235
View directory record Official record
Conditions
Diabetes
Interventions
High Saturated Fat Diet
Other
Lead sponsor
Kevin Davy
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

NCT03960008
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Burlington, Massachusetts • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

NCT00020943
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
80
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 14, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional

Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients

NCT06250309
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Dietary assignment
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise-Induced Epigenetic Modifications in Obese Aging Women

NCT01977885
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
High Protein Diet, Exercise
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
50 Years to 64 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

NCT05078138
View directory record Official record
Conditions
Exercise-Induced Anemia, Physical Performance
Interventions
Epoetin Alfa
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
12
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 14, 2026, 9:53 PM EDT